RecruitingPhase 2NCT05733598
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Studying Adult hepatocellular carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Replimune Inc.
- Principal Investigator
- May Cho, MDReplimune Inc.
- Intervention
- RP2(biological)
- Enrollment
- 60 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (11)
- Beverly Hills Cancer Center, Beverly Hills, California, United States
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- Sylvester Comprehensive Cancer Center (University of Miami Hospital and Clinics), Miami, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- University of Maryland Medical Center, Baltimore, Maryland, United States
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
- Montefiore Medical CenterMontefiore Medical Park, The Bronx, New York, United States
- University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
- The West Clinic, Germantown, Tennessee, United States
- University of Tennessee Medical Center, Knoxville, Tennessee, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05733598 on ClinicalTrials.govOther trials for Adult hepatocellular carcinoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT07441369Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases CancerFudan University
- RECRUITINGPHASE2NCT07175441Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular CarcinomaRiboscience, LLC.
- RECRUITINGPHASE2NCT07560488Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE2NCT07010497A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular CarcinomaAsan Medical Center
- RECRUITINGPHASE1, PHASE2NCT07291076A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)Bristol-Myers Squibb
- RECRUITINGPHASE1, PHASE2NCT07500220Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCCBeijing Biotech
- RECRUITINGPHASE2NCT07413354Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular CarcinomaTongji Hospital
- RECRUITINGNANCT07365527Sonoporation and Tumor Microenvironment Response in Colorectal Liver MetastasesZealand University Hospital